Literature DB >> 20166921

Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.

Patricia H Reggio1.   

Abstract

The cannabinoid CB1 and CB2 receptors are Class A G protein-coupled receptors (GPCRs). While many Class A GPCRs have endogenous ligands that are hydrophilic cations (e.g., the serotonin and dopamine receptors), the cannabinoid receptors have neutral, highly lipophilic ligands derived from the fatty acid, arachidonic acid. The most well-studied of these are N-arachidonoylethanolamine (anandamide, AEA) and sn-2-arachidonoylglycerol (2-AG). This review focuses on the experimental and computational studies that have been used to probe the nature of endocannabinoid interaction with the cannabinoid receptors. These studies include mutation, SAR and NMR studies, as well as, QSAR, docking and molecular dynamics simulations. Gaps in our knowledge are identified. The review begins more generally, however, by discussing the entire endocannabinoid system, of which the cannabinoid receptors are part. For in order to understand endocannabinoid action, one needs an appreciation for the environments for which these ligands have been designed and the conformational changes these ligands must undergo in order to act on the cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166921      PMCID: PMC4120766          DOI: 10.2174/092986710790980005

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  194 in total

Review 1.  Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.

Authors:  D Shire; B Calandra; M Bouaboula; F Barth; M Rinaldi-Carmona; P Casellas; P Ferrara
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

2.  Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.

Authors:  P Massi; D Fuzio; D Viganò; P Sacerdote; D Parolaro
Journal:  Eur J Pharmacol       Date:  2000-01-17       Impact factor: 4.432

3.  Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.

Authors:  J A Javitch; D Fu; G Liapakis; J Chen
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

4.  GPCR structure-based virtual screening approach for CB2 antagonist search.

Authors:  Jian-Zhong Chen; Junmei Wang; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2007-06-20       Impact factor: 4.956

5.  LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.

Authors:  C C Felder; K E Joyce; E M Briley; M Glass; K P Mackie; K J Fahey; G J Cullinan; D C Hunden; D W Johnson; M O Chaney; G A Koppel; M Brownstein
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

6.  1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor.

Authors:  John W Huffman; Simon M Bushell; John R A Miller; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2002-12       Impact factor: 3.641

Review 7.  Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.

Authors:  P H Reggio; H Traore
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

8.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.

Authors:  T Sheskin; L Hanus; J Slager; Z Vogel; R Mechoulam
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

9.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.

Authors:  V Abadji; S Lin; G Taha; G Griffin; L A Stevenson; R G Pertwee; A Makriyannis
Journal:  J Med Chem       Date:  1994-06-10       Impact factor: 7.446

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  53 in total

1.  Distance measurements and conformational analysis of sn-2-arachidonoylglycerol-membrane sample by ²H-³¹P REDOR NMR.

Authors:  Elvis K Tiburu; Lingling Shen
Journal:  J Membr Biol       Date:  2014-01-09       Impact factor: 1.843

2.  Cannabinoids Activate Monoaminergic Signaling to Modulate Key C. elegans Behaviors.

Authors:  Mitchell D Oakes; Wen Jing Law; Tobias Clark; Bruce A Bamber; Richard Komuniecki
Journal:  J Neurosci       Date:  2017-02-10       Impact factor: 6.167

Review 3.  A patent update on cannabinoid receptor 1 antagonists (2015-2018).

Authors:  George Amato; Nayaab S Khan; Rangan Maitra
Journal:  Expert Opin Ther Pat       Date:  2019-04-08       Impact factor: 6.674

4.  Selective Cannabinoid 2 Receptor Stimulation Reduces Tubular Epithelial Cell Damage after Renal Ischemia-Reperfusion Injury.

Authors:  Jeffrey D Pressly; Suni M Mustafa; Ammaar H Adibi; Sahar Alghamdi; Pankaj Pandey; Kuldeep K Roy; Robert J Doerksen; Bob M Moore; Frank Park
Journal:  J Pharmacol Exp Ther       Date:  2017-11-29       Impact factor: 4.030

5.  Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.

Authors:  Dennis W Szymanski; Malvina Papanastasiou; Katja Melchior; Nikolai Zvonok; Richard W Mercier; David R Janero; Ganesh A Thakur; Sangwon Cha; Billy Wu; Barry Karger; Alexandros Makriyannis
Journal:  J Proteome Res       Date:  2011-09-13       Impact factor: 4.466

Review 6.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

7.  Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands.

Authors:  Rareş-Petru Moldovan; Kristin Hausmann; Winnie Deuther-Conrad; Peter Brust
Journal:  ACS Med Chem Lett       Date:  2017-04-28       Impact factor: 4.345

8.  Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.

Authors:  Alan Fulp; Katherine Bortoff; Yanan Zhang; Herbert Seltzman; James Mathews; Rodney Snyder; Tim Fennell; Rangan Maitra
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

Review 10.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.